title: Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception.
abstract: OBJECTIVE
  To compare the effectiveness and acceptability of three regimens of postcoital contraception.
  
  
  METHODS
  Randomised group comparison of ethinyloestradiol 100 micrograms plus levonorgestrel 500 micrograms repeated after 12 hours (Yuzpe method); danazol 600 mg repeated after 12 hours; and mifepristone 600 mg single dose.
  
  
  METHODS
  Community family planning clinic.
  
  
  METHODS
  616 consecutive women with regular cycles aged 16 to 45 years.
  
  
  METHODS
  Number of pregnancies, incidence of side effects, and timing of next period.
  
  
  RESULTS
  The raw pregnancy rates (with 95% confidence intervals) for the Yuzpe, danazol, and mifepristone groups were 2.62% (0.86% to 6.00%), 4.66% (2.15% to 8.67%), and 0% (0% to 1.87%) respectively. Overall, these rates differed significantly (chi 2 = 8.988, df = 2; p = 0.011). The differences between the mifepristone and Yuzpe groups and between the mifepristone and danazol groups were also significant. Side effects were more common and more severe in the Yuzpe group (133 women (70%)) than in either the danazol group (58 (30%)) or the mifepristone group (72 (37%)). The Yuzpe regimen tended to induce bleeding early but mifepristone prolonged the cycle. Three women bled more than seven days late in the Yuzpe group compared with 49 in the mifepristone group.
  
  
  CONCLUSIONS
  Mifepristone was effective in reducing expected pregnancy rates and the Yuzpe method also had a clinical effect. Danazol had little or no effect. A further multicentre trial is needed.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Manchester.
authors.forename: A M
authors.initials: AM
authors.lastname: Webb
authors.forename: J
authors.initials: J
authors.lastname: Russell
authors.forename: M
authors.initials: M
authors.lastname: Elstein
mesh_terms: D000293:Adolescent; D000328:Adult; D003277:Contraceptives, Oral, Combined; D003281:Contraceptives, Postcoital; D003613:Danazol / Q000009:adverse effects / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000009:adverse effects / Q000494:pharmacology; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D015735:Mifepristone / Q000009:adverse effects / Q000494:pharmacology; D009325:Nausea / Q000139:chemically induced; D011247:Pregnancy; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D003277:Contraceptives, Oral, Combined; D003281:Contraceptives, Postcoital; D015735:Mifepristone; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D003613:Danazol